PRDM9 and Familial prostate cancer: Inhibits the histone methyltransferase activity of EZH2 while inducing degradation of the PRC2 core subunits EZH2, EED, and SUZ12. In immunocompromised mice, this compound reduced the time of formation of tumors originating from prostate cancer cells